- Home
- CGNT vs STOK Comparison
CGNT vs STOK Comparison
Compare CGNT & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGNT
- STOK
- Stock Information
- Founded
- CGNT 2020
- STOK 2014
- Country
- CGNT Israel
- STOK United States
- Employees
- CGNT N/A
- STOK N/A
- Industry
- CGNT Computer Software: Prepackaged Software
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- CGNT Technology
- STOK Health Care
- Exchange
- CGNT Nasdaq
- STOK Nasdaq
- Market Cap
- CGNT 669.2M
- STOK 638.8M
- IPO Year
- CGNT N/A
- STOK 2019
- Fundamental
- Price
- CGNT $9.23
- STOK $12.03
- Analyst Decision
- CGNT Hold
- STOK Strong Buy
- Analyst Count
- CGNT 1
- STOK 5
- Target Price
- CGNT N/A
- STOK $24.50
- AVG Volume (30 Days)
- CGNT 431.3K
- STOK 541.2K
- Earning Date
- CGNT 09-09-2025
- STOK 08-06-2025
- Dividend Yield
- CGNT N/A
- STOK N/A
- EPS Growth
- CGNT N/A
- STOK N/A
- EPS
- CGNT N/A
- STOK 0.88
- Revenue
- CGNT $363,466,000.00
- STOK $190,908,000.00
- Revenue This Year
- CGNT $14.94
- STOK $378.84
- Revenue Next Year
- CGNT $9.57
- STOK N/A
- P/E Ratio
- CGNT N/A
- STOK $13.80
- Revenue Growth
- CGNT 12.58
- STOK 2333.81
- 52 Week Low
- CGNT $6.21
- STOK $5.35
- 52 Week High
- CGNT $11.66
- STOK $16.15
- Technical
- Relative Strength Index (RSI)
- CGNT 42.60
- STOK 67.00
- Support Level
- CGNT $8.98
- STOK $11.19
- Resistance Level
- CGNT $9.25
- STOK $12.00
- Average True Range (ATR)
- CGNT 0.26
- STOK 0.54
- MACD
- CGNT 0.00
- STOK -0.04
- Stochastic Oscillator
- CGNT 54.61
- STOK 75.30
About CGNT Cognyte Software Ltd.
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.